An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

After years of rising obesity rates in the US, the numbers dipped slightly during 2023, though experts disagree about the ...

Mounjaro, like Ozempic, is a GLP-1 inhibitor – a class of drugs developed to help people with diabetes regulate their blood ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...